Recent Updates
Recently added Catalysts
BLTE Positive Sentiment Score: 75/100

Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th

Key Takeaway: Belite Bio, Inc (NASDAQ: BLTE) announced that its Chief Science Officer, Dr. Nathan L. Mata, will present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on May 15, 2025. This online event is designed to connect global companies with ADR programs to potential investors. Belite Bio is currently advancing its drug development programs, including a pivotal Phase 3 trial for Tinlarebant targeting Stargardt disease, which is expected to be completed by Q4 2025. The company received a favorable recommendation for drug approval following an interim analysis of the trial.

Market Sentiment Analysis

POSITIVE FACTORS

  • Belite Bio is focused on advancing novel therapeutics for degenerative retinal diseases.
  • The company's CSO will present at a key investor conference, enhancing visibility.
  • The DRAGON trial's positive interim analysis could lead to drug approval.

Full Press Release Details

SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that CSO, Dr. Nathan L. Mata will present at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference on May 15, 2025. This virtual investor conference is aimed exclusively at introducing global companies with ADR programs to investors.
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Participation is free of charge.
Recent Company Highlights
DRAGON trial, a pivotal global Phase 3 trial of Tinlarebant in adolescent Stargardt disease (STGD1) subjects is expected to be completed by Q4 2025
Following a pre-specified interim analysis, an independent DSMB recommended to submit the interim analysis data of DRAGON trial for further regulatory review for drug approval
Pivotal global Phase 3 PHOENIX trial of Tinlarebant in geographic atrophy (GA) subjects is ongoing with more than 460 subjects enrolled
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
Virtual Investor Conferences
SVP Corporate Services, Investor Access

Frequently Asked Questions

When will Belite Bio present at the investor conference?

Belite Bio will present on May 15, 2025, at the dbVIC Virtual Investor Conference.

What is the focus of Belite Bio's drug development?

Belite Bio focuses on novel therapeutics for degenerative retinal diseases.

Is there a cost to participate in the virtual event?

Participation in the virtual investor conference is free of charge.

How can investors join the event online?

Investors are encouraged to pre-register and run an online system check to join.

What is the DRAGON trial focused on?

The DRAGON trial targets adolescent Stargardt disease (STGD1) patients.

Last updated: May 12, 2025